+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness of two chemotherapy combinations, 5-FU with nanoliposomal irinotecan NALIRI and 5-FU with nanoliposomal irinotecan plus oxaliplatin NALIRINOX, in patients with metastatic pancreatic ductal adenocarcinoma PDAC who have progressed after treatment with Gemcitabine-Abraxane or Gemcitabine alone. This phase 2 randomized study aims to assess the progression-free survival rate and safety of these treatments in fit patients with good performance status. Participants receive treatment in 14-day cycles. In the NALIRI group, patients are given leucovorin, nanoliposomal irinotecan at 70 mgm, and 5-FU through intravenous infusion. The NALIRINOX group receives oxaliplatin, leucovorin, nanoliposomal irinotecan at 50 mgm, and 5-FU. The study monitors dosing adjustments based on individual tolerance, especially for patients with specific genetic markers. Treatments are administered mostly via intravenous infusions over several hours and continuous infusions over two days. During the study, participants undergo regular imaging scans, tumor marker tests, and safety assessments to evaluate treatment response and side effects. Researchers track progression-free survival at day 85 post-randomization and continue monitoring survival and disease control for up to five years. Safety is closely followed through laboratory tests, physical exams, and adverse event reporting until two weeks after treatment ends. The total participation time varies depending on individual treatment response and follow-up duration.

Age: 18Years +All GendersPhase 2
13 locations
P

Actively Recruiting

Researchers are evaluating a new treatment approach for colon cancer, focusing on a specific type called mismatch repair proficientmicrosatellite stable MMRpMSS colon cancer. This Phase 2 study compares a combination of dostarlimab with CAPEOX chemotherapy to CAPEOX chemotherapy alone. The study aims to find early signs of how well this combination works before surgery and to understand how blood and tumor markers might predict treatment response. Participants will be randomly assigned to receive either dostarlimab plus CAPEOX chemotherapy or CAPEOX chemotherapy alone. Both treatments are given before surgery, a process known as neoadjuvant therapy. The study includes two groups one receiving the combination treatment and the other receiving only chemotherapy. Treatment duration and follow-up are planned to assess response and safety. During the study, participants will undergo various assessments including tumor tissue collection via colonoscopy, evaluations of tumor response, and monitoring for adverse events. Researchers will measure major pathological response rates and track any side effects up to approximately 105 weeks. The study also looks at the percentage of participants who can undergo tumor removal surgery, and detailed pathological response rates. Safety and effectiveness are monitored throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
33 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
B

Actively Recruiting

Central sleep apnea CSA involves periods during sleep when breathing temporarily stops or decreases due to a lack of effort to breathe. This condition can cause excessive daytime sleepiness and poor sleep quality and is linked to higher mortality in patients with heart failure. Researchers are studying the factors that influence treatment choices and how well patients follow these treatments for CSA in Belgium, as well as the effects of these treatments. Participants in this study will receive routine care as part of a registry, without additional interventions from the study. Eligible participants have a confirmed diagnosis of CSA based on specific breathing event measurements from sleep studies. This observational study will follow patients over five years to monitor their treatment decisions, compliance with treatments, and health outcomes. Throughout the study, participants treatment choices and compliance will be tracked along with assessments of their health-related quality of life and sleep quality using surveys like the Short Form 36 Health Survey and Pittsburgh Sleep Quality Index. Researchers will also monitor mortality over the five-year period. The study involves regular evaluations but no experimental treatments, focusing on real-world data collection to better understand CSA management.

Age: 18Years +All Genders
14 locations
S

Actively Recruiting

Researchers are evaluating whether taking a low dose of colchicine daily, alongside standard treatment, can reduce cardiovascular events in patients with coronary artery disease CAD after treatment with percutaneous coronary intervention PCI. This phase III randomized, double-blind, placebo-controlled trial aims to confirm if colchicine helps prevent further incidents in CAD and to identify patients who might benefit most from this treatment. Participants will be randomly assigned to receive either colchicine 0.5 mg or a matching placebo once daily, in addition to their standard care. The trial plans to enroll up to 2770 participants and will continue until 566 primary endpoint events occur. Follow-up includes a clinic visit one month after randomization, then annual visits with additional telephone check-ins every six months. Throughout the study, participants will complete questionnaires and have their health outcomes monitored to assess events like death, heart attacks, strokes, and need for further coronary procedures over 44 months. Researchers will also evaluate patient-reported outcomes including angina frequency, breathlessness, depression, and quality of life. Medication adherence and safety will be closely tracked during scheduled visits and calls.

Age: 45Years +All GendersPhase 3
19 locations
R

Actively Recruiting

Researchers are investigating head and neck squamous cell carcinomas HNSCC located in the oral cavity, oropharynx, larynx, or hypopharynx, specifically in patients with positive lymph nodes on only one side of the neck and no distant metastasis. The study focuses on evaluating two strategies the use of sentinel lymph node mapping to customize the areas of the neck to be irradiated and reducing the radiation dose. This research aims to decrease the volume and dose of radiation to the contralateral neck to minimize severe side effects while maintaining cancer control. Participants will undergo different radiotherapy approaches based on sentinel lymph node mapping results. If the scan shows drainage only on the tumor side and the tumor does not cross the midline, patients will receive radiation on the same side with a reduced dose, sparing the opposite side. If drainage to the opposite side is present, participants will be randomly assigned to either receive radiation to the entire lymph node level containing the sentinel node or only to the sentinel node itself, both at reduced doses. The treatment targets are adapted individually according to the lymph node drainage pattern. During the study, patients will be monitored for contralateral regional control over two years after radiotherapy. Quality of life questionnaires will be completed regularly during the first two years. Researchers will also assess normal tissue complication probability, local cancer control, overall survival, and radiotherapy-induced toxicity. The study includes imaging assessments and clinical evaluations to measure treatment effects and safety, with follow-up visits scheduled up to two years post-treatment.

Age: 18Years +All GendersPhase Not Applicable
10 locations
E

Actively Recruiting

Researchers are collecting real-world data from cancer patients who receive radiotherapy to better understand the role of radiation oncology within a multidisciplinary treatment approach. This open-ended, prospective, non-interventional study aims to support radiotherapy research by observing patients over time without providing therapeutic interventions. The study includes patients with various cancer types who are planned to receive radiotherapy. Participants include patients treated with radical radiotherapy for oligometastatic disease as well as those receiving high-dose re-irradiation. The study is organized into multiple cohorts, such as OligoCare and ReCare, based on the type of radiotherapy treatment. Since it is an observational study, no experimental treatments or placebos are given. During the study, researchers will collect data on patient outcomes including disease-free survival, loco-regional control, distant metastasis-free survival, overall survival, and any adverse events related to radiotherapy over a period of five years. The main measure is the number of patients treated with radiotherapy enrolled in the program. Participants will have their health and treatment effects monitored regularly throughout this timeframe to provide valuable information about radiotherapy outcomes in real-world clinical settings.

Age: 12Years +All Genders
77 locations
P

Actively Recruiting

Researchers are investigating whether preventive radiotherapy can reduce symptoms and complications in patients with metastatic cancer who have high-risk bone metastases that cause no or minimal symptoms. This study focuses on determining if early radiation treatment, in addition to standard medication or observation, can lower the number of skeletal-related events, reduce hospitalizations, improve survival, and enhance quality of life. The study is a multi-center, randomized phase 3 trial involving patients with various solid tumors prone to bone metastases. Participants will be randomly assigned to one of two groups one receiving standard systemic therapy or observation alone, and the other receiving preventive radiotherapy plus standard therapy or observation. Radiotherapy may be a single dose or stereotactic ablative body radiation delivered within 21 days after randomization. During follow-up, patients in the radiotherapy group may receive additional preventative radiation for new high-risk bone metastases, with up to five lesions treated at once. Participants will undergo screening to confirm eligibility, including assessments of medical history, quality of life, and pain for each bone lesion. Follow-up visits will occur at 1, 3, 6, 12, 18, and 24 months after randomization to monitor safety, efficacy, side effects, medication use, pain, and quality of life through questionnaires. In case of skeletal-related events, assessments will be done promptly, and survival and hospitalization data will continue to be recorded until 24 months post-randomization.

Age: 18Years +All GendersPhase Not Applicable
8 locations
C

Actively Recruiting

Researchers are evaluating standard neoadjuvant treatment options for patients aged 70 years or older with high-risk stage II and stage III rectal cancer in a multicentre, open-label, randomized clinical trial called SHAPERS. The study compares conventional neoadjuvant therapy with total neoadjuvant therapy TNT to understand their safety and effectiveness for this older patient group. Participants are randomly assigned to one of two groups. The conventional treatment group receives either short course radiotherapy followed by surgery or watch & wait, with optional adjuvant chemotherapy, or long course chemoradiotherapy followed by surgery or watch & wait, also with optional adjuvant chemotherapy. The TNT group receives one of several treatment regimens decided by the investigator before randomization, including combinations of short course radiotherapy, oxaliplatin-based chemotherapy lasting up to 18 weeks, and chemoradiotherapy, followed by surgery or watch & wait. During the study, participants undergo treatments as assigned and are monitored for outcomes including overall survival, progression-free survival, peripheral sensory neuropathy, and severe toxicities over 3 years after randomization. Researchers will gather information about treatment effects, side effects, and patient survival to compare the two approaches. The study includes follow-up assessments to track these outcomes and participant safety throughout the trial duration.

Age: 70Years +All GendersPhase Not Applicable
19 locations

1-10 of 17

1